Selective targeting of siRNA to ovarian carcinoma, using biocompatible nanoparticles.

摘要

A novel drug delivery platform has been developed for the systemic delivery of anti-cancer drugs utilizing reconstituted /synthetic high density lipoprotein (rHDL) nanoparticles (1). This vehicle is preferred over conventional drug delivery strategies because its small size and biocompatible components (2). A further advantage of the rHDL model is the selective uptake mechanism (3) whereby anti-cancer agents are delivered to target cells while avoiding normal cells. In addition to transporting lipophilic drugs, we have been able utilize rHDL nanoparticles for the delivery and retention of specific siRNAs to ovarian cancer cells, resulting in marked tumor ablation in mice with broad implications for a novel and highly effective cancer therapy.